Zevra Therapeutics: A Rare Disease Powerhouse Set to Report 2024 Financial Results

Zevra Therapeutics, Inc. (ZVRA), a commercial-stage company focused on providing therapies for people living with rare diseases, is set to report its corporate and financial results for the fourth quarter and full year 2024 on Tuesday, March 11, 2025. The Company will issue a news release after the market closes and host a conference call/audio webcast at 4:30 p.m. ET that day. Investors can access the webcast through Zevra's investor relations website, with dial-in options available for both U.S. and international participants using Conference ID: ZVRAQ424. A replay of the webcast will be available for 90 days following the presentation.

Zevra Therapeutics has made significant strides in its mission to bring life-changing therapeutics to people living with rare diseases. With a diverse portfolio of products and product candidates, the Company has demonstrated its commitment to addressing unmet needs in the rare disease space. Some of Zevra's key products and product candidates include:

1. Arimoclomol (MIPLYFFA™): Approved by the FDA in September 2024, MIPLYFFA™ is an orally delivered treatment for neurological manifestations of Niemann-Pick disease type C (NPC) in adult and pediatric patients 2 years of age and older. The approval of MIPLYFFA™ has opened up new revenue streams for Zevra and has been met with enthusiasm from the NPC community. As of October 31, 2024, Zevra has received 90 prescription enrollment forms for MIPLYFFA™, with 30% already approved for reimbursement and ready for fulfillment upon drug availability.
2. KP1077: Zevra's lead clinical development product candidate is being developed as a treatment for idiopathic hypersomnia (IH) and narcolepsy. Although there is no specific revenue data provided for KP1077, its potential in the rare neurological sleep disorder market presents an opportunity for future expansion.
3. AZSTARYS®: This once-daily treatment for attention deficit hyperactivity disorder (ADHD) in patients aged six years and older has contributed to Zevra's revenue growth. The product contains the prodrug serdexmethylphenidate (SDX) and d-methylphenidate (d-MPH).
4. OLPRUVA®: This commercial product has also shown promise, with three new patient enrollments in the third quarter and reimbursement coverage at approximately 76% of covered lives. Zevra is refining its commercial strategy for OLPRUVA to focus on specific patient segments where there are fewer access barriers.



Zevra's approach to clinical development and commercialization has allowed the company to build a strong pipeline of products and product candidates, which has positively impacted its financial outlook and valuation. The successful launch of MIPLYFFA™, along with the company's other commercial products such as OLPRUVA® and AZSTARYS®, has contributed to Zevra's revenue growth. In the third quarter of 2024, the company reported revenue of $3.7 million, comprised of $2.6 million in net reimbursements from the French expanded access program (EAP) for arimoclomol, $1.1 million of royalties and other reimbursements under the AZSTARYS® license agreement, and other sources.

Furthermore, Zevra's receipt of a rare pediatric disease Priority Review Voucher (PRV) following the FDA approval of MIPLYFFA™ has enhanced the company's financial outlook and valuation. The PRV can be monetized to help fund Zevra's growth and support its continued expansion in the rare disease space.

In conclusion, Zevra Therapeutics' strategic focus on rare diseases has contributed to its financial performance in 2024, and investors can expect to see trends that reflect the company's continued commitment to this market in the fourth quarter and full year results. The company's diverse portfolio of products and product candidates, successful clinical development and commercialization strategies, and strong financial outlook position it well for future growth and success. As Zevra reports its 2024 financial results, investors should pay close attention to the company's progress in its rare disease therapies and the potential for future expansion in this promising market.